Barclays Initiates Coverage On 4D Molecular Therapeutics with Overweight Rating, Announces Price Target of $45
Portfolio Pulse from Benzinga Newsdesk
Barclays has initiated coverage on 4D Molecular Therapeutics (FDMT) with an Overweight rating and set a price target of $45.
April 15, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays initiated coverage on 4D Molecular Therapeutics with an Overweight rating and a price target of $45.
The initiation of coverage by Barclays with an Overweight rating and a high price target suggests a positive outlook on FDMT's stock, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100